The Alkaloid #1: The White House Just Opened the Door

As federal policy shifts, psilocybin moves from counterculture to clinic.

THE DOSE

The White House Just Opened the Door

Four days ago, President Trump signed an executive order that may be the most consequential federal policy shift in the history of psychedelic medicine. The order — titled Accelerating Medical Treatments for Serious Mental Illness — directs the FDA to fast-track review of psilocybin, ibogaine, and MDMA, allocates $50 million in federal matching funds for state research programs, and expands Right to Try access for patients with serious mental health conditions.

This is not a legalization order. It is something more surgical — and in the long run, potentially more powerful.

By running psychedelics through the FDA medical pathway rather than a legalization or scheduling reform route, the White House has effectively handed the keys to pharmaceutical infrastructure. If psilocybin clears FDA approval — and Compass Pathways is preparing a full drug application for Q4 2026, with Priority Review Vouchers now potentially cutting review time to six to eight weeks — it arrives not as a counterculture relic but as a prescription medicine. Covered by insurance. Administered in clinics. Studied in VA hospitals.

The cultural implications are as significant as the clinical ones. Psychedelics spent sixty years as the defining symbol of federal prohibition. They are now being endorsed in the Oval Office, with veterans and senators from both parties applauding. Whatever you think of the politics, the Overton window didn't just move — it relocated.

For cannabis, the ripple effect is worth watching closely. Legal experts and industry advocates are already arguing that the medical-first framework being built for psychedelics is the exact model cannabis rescheduling needs to follow. The infrastructure being constructed for one will inevitably serve the other.

QUICK HITS

Hemp THC ban incoming. Senators Rand Paul, Amy Klobuchar, and Joni Ernst filed a bill allowing states and tribal nations to opt out of the federal recriminalization of hemp THC products set to take effect in November. The clock is ticking for the hemp-derived cannabinoid market.
Louisiana moves on psychedelic therapy. The Louisiana Senate passed a bill establishing a psychedelic-assisted therapy pilot program, funded by opioid settlement dollars. Psilocybin and ibogaine are both in scope.
Massachusetts freezes cultivation licenses. State regulators voted to halt new cannabis cultivation license issuance. Supply concerns or market correction — the interpretation depends on who you ask.
Compass Pathways surged. Following the executive order, Compass Pathways stock jumped sharply alongside Cybin and other psychedelics-focused developers. Investors are treating the order as a starting gun.
Australia leads, Europe follows. Australia already permits psychiatrist-prescribed psilocybin for treatment-resistant depression. The Czech Republic legalized psilocybin-assisted therapy in January. Germany launched the EU's first compassionate access program in 2025. The U.S. is catching up, not leading.

SCIENCE DESK

What ibogaine actually is — and why it's complicated

Of all the compounds named in Trump's executive order, ibogaine is the most explicitly mentioned and the most medically contested. Derived from the root bark of the African Tabernanthe iboga shrub, ibogaine produces an intense, multi-hour psychedelic experience that has shown remarkable results in interrupting opioid and alcohol addiction — sometimes after a single dose.

The catch is cardiac risk. Ibogaine can prolong the QT interval in the heart, creating a potential arrhythmia risk that has contributed to deaths in uncontrolled settings. Most ibogaine research has been conducted abroad precisely because the FDA has historically resisted trials on safety grounds.

The executive order sidesteps this tension somewhat by invoking Right to Try — the federal law allowing terminally or seriously ill patients access to experimental drugs after Phase I trials. Legal experts note that ibogaine has not clearly met that Phase I threshold, making its explicit inclusion in the order legally unusual. What happens next will likely be decided in clinical trial design, not courtrooms.

MARKET WATCH

The psychedelics executive order created immediate movement in public markets. Compass Pathways, Cybin, and AtaiBeckley all saw significant single-day gains following the signing. The underlying thesis — that FDA approval of psilocybin is now a matter of when rather than if — is being priced in early.

Cannabis markets remain more complicated. Federal rescheduling under the prior administration's order remains, in Trump's own words, being "slow-walked" by the DOJ. The hemp-derived THC sector faces November's recriminalization deadline with no clear federal resolution. State-by-state divergence continues: South Dakota's medical program grew 62% in patient count over the past year, while Massachusetts freezes new cultivation licenses.

The investment signal right now: psychedelics biotech has a cleaner near-term catalyst than cannabis. But the regulatory groundwork being laid today will determine which companies are positioned when cannabis federal reform eventually moves.

THE LAST WORD

There is something worth sitting with in this moment. The same federal government that spent sixty years criminalizing psychedelics — disproportionately incarcerating Black and brown communities in the process — is now allocating $50 million to research them. The compounds that healers, indigenous traditions, and underground therapists never stopped working with are being rediscovered by institutions that banned them.

That is not cynicism. It is context.

The opportunity here is real. FDA-approved psilocybin could reach millions of people for whom antidepressants have failed. Ibogaine could interrupt addiction cycles that have devastated entire communities. These outcomes matter enormously and are worth fighting for.

But the shape of access will define whether this moment is transformative or extractive. If psychedelic medicine arrives exclusively through $400 clinic sessions and pharmaceutical patents, the people most harmed by the war on drugs will be the last to benefit from its undoing.

The science is finally getting its hearing. The harder work — making sure the healing reaches everyone — is just beginning.

— The Alkaloid

The Alkaloid publishes every Tuesday. Forward this to someone who needs the dose. Subscribe for full access: TheAlkaloid.Ghost.io

Sources